Sanjivani ParanteralQ1 FY25

Sanjivani Paranteral Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹166.8P/E: 20.6Market Cap: ₹205 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

No

Order

N/A

Capex

No

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • Base business expected to grow at approximately 25% year-on-year.
  • HAL joint venture projected to contribute one quarter of revenue in FY ‘25 and a full year in FY ‘26.
  • Prague joint venture operational with initial orders executed; full operational capacity expected by end of August or September 2024.
  • Growth from strategic partnerships with five state PSUs and potential expansion via Public-Private Partnership (PPP) models.
  • Expansion into new geographies including Africa, Central America, Middle East, and Latin America.
  • Focus on complex products and higher value-addition segments, with plans to grow injectable segment alongside nutraceuticals via Prague.
  • Logistics and geopolitical uncertainty (e.g., Middle East tensions) present challenges affecting order flow and costs.
  • No major immediate funding required; prior preferential raise funded January 2024 projects.

See what Sanjivani Paranteral management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • Currently, Sanjivani Paranteral Limited has no debt on its books and plans to maintain a debt-free status.
  • There are no ongoing plans or requirements for new debt funding.
  • Regarding equity or other funding for future investments, no additional funds are needed at present.
  • Recent projects mentioned were funded earlier in January through a preferential equity raise, as disclosed in Stock Exchange documents.
  • No immediate fundraising activities are planned since existing funds cover current projects, and no new opportunities requiring funding have been identified.

See what Sanjivani Paranteral management said on order book — free account, 30 seconds.

Capex plans

No
  • The company currently does not require additional funds for projects; recent investments were raised through a preferential raise in January.
  • For the base business growth (around 20-25% YoY), no major incremental CAPEX is expected beyond ongoing maintenance and upgrades.
  • Planned CAPEX of Rs. 10-12 crores is for basic upgrades and regulatory inspections, spread over this and next financial year, not as an annual recurring expense.
  • The HAL Joint Venture has a development timeline of 9-12 months for production start, with commercial operations expected by October 2024.
  • The Prague JV is partially operational, with full-scale operations anticipated by end of August or September 2024.
  • The company is exploring strategic partnerships, mainly with government PSUs and potential collaborations in oncology and hormone therapeutic areas, though no immediate new collaborations confirmed.

Track Sanjivani Paranteral — get its next earnings analysis in your feed

How does Sanjivani Paranteral rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSanjivani Paranteral
Rev 2Mar 3

How does Sanjivani Paranteral rank in Pharmaceuticals & Biotechnology?

Compare Sanjivani Paranteral against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →